<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=384506&amp;fmt=gif">
Skip to content
    July 20, 2011

    Drug Repositioning Conference Highlights

    From both big pharma and more specialized drug repositioning companies presenting at the Drug Repositioning Conference in San Francisco last week, it became clear that if one can get an IP hook, the strategy allows one to quickly create significant monetizable value with a relatively small investment.

    drug-repositioning2

    from: http://dx.doi.org/10.1016/j.drudis.2012.08.005

    To highlight two memorable examples:

    1. Cephalon bought bdc for $70m with just an “animal use patent” for sciatica  to compete w/ Amgen’s Embrel
    2. Adolor repositioned the potential anti-depressant Org4428 that stalled at phase 3 for depression as a non-opioid for pain, received a fast-track use patent, and successfully partnered the program with Organon (which was acquired by Schering-Plough, now Merck).

    Bottom line is if you can show differentiation, capture IP, and show a cost-benefit commercial path to market, then repurposing is a fast (perhaps the fastest) route to an approved drug.

    Barry Bunin chaired a webinar panel with Chris Lipinski, David Cavalla and Noel Southall.  Download the talks below. We’ll provide full talk transcripts and archive these materials on the CDD Resources page for easy reference.

    Tag(s):

    Other posts you might be interested in

    View All Posts
    CDD Blog
    9 min   March 26, 2024
    Drug Discovery Industry Roundup with Barry Bunin — March 26, 2024
    Read More
    CDD Blog
    2 min   March 26, 2024
    Recorded Webinar: Trends & Better Practices for the Use of Gen AI & LLMs
    Read More
    CDD Blog
    2 min   March 22, 2024
    Recorded Webinar: Interdisciplinary Pathways in Medicine- from Neurodegenerative to Oncology Disease Research and Drug Discovery
    Read More